Document Classification

Section Type: RESULTS

Text: After 28 days of therapy, exenatide was associated with significant (P < 0. 0001, linear contrast testing), dose-dependent reductions in HbA 1c (0. 1 + / - 0. 1 %, -0. 3 + / - 0. 1 %, -0. 4 + / - 0. 1 %, + / -0. 5 + / - 0. 0 %, and -0. 5 + / - 0. 1 % for placebo and 2. 5, 5. 0, 7. 5, and 10. 0 microg b. i. d. exenatide, respectively) and significant (P = 0. 0006, linear contrast testing) reductions in fasting plasma glucose (+6. 8 + / - 4. 1, -20. 1 + / - 5. 2, -21. 2 + / - 3. 9, -17. 7 + / - 4. 8, and -17. 3 + / - 4. 4 mg/dL for placebo and 2. 5, 5. 0, 7. 5, and 10. 0 microg b. i. d. exenatide, respectively) by Day 28.